Alexion Pharmaceuticals I... (ALXN)
NASDAQ: ALXN
· Real-Time Price · USD
182.50
0.00 (0.00%)
At close: Apr 24, 2025, 3:47 PM
Alexion Pharmaceuticals Revenue Breakdown
| Period Ending | Mar 31, 2021 | Dec 31, 2020 | Sep 30, 2020 | Jun 30, 2020 | Mar 31, 2020 | Sep 30, 2019 | Jun 30, 2019 | Mar 31, 2019 |
|---|---|---|---|---|---|---|---|---|
| Net Product Sales Revenue | 1.64B | 1.59B | 1.59B | 1.44B | 1.44B | 1.26B | 1.2B | 1.14B |
| Net Product Sales Revenue Growth | +2.76% | +0.21% | +9.96% | -0.01% | +14.37% | +5.04% | +5.46% | n/a |
| Other Revenue Revenue | 800K | n/a | 400K | 100K | 200K | n/a | 800K | 200K |
| Other Revenue Revenue Growth | n/a | n/a | +300.00% | -50.00% | n/a | -100.00% | +300.00% | n/a |
Revenue by Geography
| Period Ending | Mar 31, 2021 | Sep 30, 2020 | Jun 30, 2020 | Mar 31, 2020 | Sep 30, 2019 | Jun 30, 2019 | Mar 31, 2019 |
|---|---|---|---|---|---|---|---|
| Ultomiris Revenue | 346.9M | 289.3M | 251.1M | 222.8M | 89.9M | 54.2M | 24.6M |
| Ultomiris Revenue Growth | +19.91% | +15.21% | +12.70% | +147.83% | +65.87% | +120.33% | n/a |
Operating Expense Breakdown
| Period Ending | Mar 31, 2021 | Dec 31, 2020 | Sep 30, 2020 | Jun 30, 2020 | Mar 31, 2020 | Dec 31, 2019 | Sep 30, 2019 | Jun 30, 2019 | Mar 31, 2019 | Dec 31, 2018 | Sep 30, 2018 | Jun 30, 2018 | Mar 31, 2018 | Dec 31, 2017 | Sep 30, 2017 | Jun 30, 2017 | Mar 31, 2017 | Dec 31, 2016 | Sep 30, 2016 | Jun 30, 2016 | Mar 31, 2016 | Dec 31, 2015 | Sep 30, 2015 | Jun 30, 2015 | Mar 31, 2015 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Selling, General, and Administrative Revenue | 342.9M | 444.4M | 334.2M | 301.4M | 319.9M | 381M | 299.3M | 299.3M | 281.5M | 318.7M | 258.7M | 277.3M | 257.1M | 296.4M | 271M | 265M | 262M | 259.51M | 230.13M | 231.8M | 232.56M | 241.58M | 212.52M | 221.38M | 187.12M |
| Selling, General, and Administrative Revenue Growth | -22.84% | +32.97% | +10.88% | -5.78% | -16.04% | +27.30% | 0.00% | +6.32% | -11.67% | +23.19% | -6.71% | +7.86% | -13.26% | +9.37% | +2.26% | +1.15% | +0.96% | +12.77% | -0.72% | -0.33% | -3.73% | +13.67% | -4.00% | +18.31% | n/a |
| Research and Development Revenue | 289.1M | 295M | 285.9M | 221.1M | 200.9M | 269.6M | 232.9M | 187.6M | 195.9M | 205.6M | 174.8M | 173.4M | 176.6M | 265.4M | 195M | 199M | 219M | 205.71M | 195.69M | 179.31M | 176.29M | 191.03M | 165.66M | 131.69M | 221.08M |
| Research and Development Revenue Growth | -2.00% | +3.18% | +29.31% | +10.05% | -25.48% | +15.76% | +24.15% | -4.24% | -4.72% | +17.62% | +0.81% | -1.81% | -33.46% | +36.10% | -2.01% | -9.13% | +6.46% | +5.12% | +9.13% | +1.71% | -7.72% | +15.31% | +25.80% | -40.43% | n/a |